Privately, some shareholders have been scathing about the tactics Mylan used to defend itself from a hostile takeover  by Teva. Photograph: Getty Images

Mylan, the generic drugs group, has launched a staunch defence of the tactics it used to repel a $40 billion hostile takeover attempt by Teva, amid po(...)

Cortendo focuses on developing drugs to treat rare endocrine diseases, including the potentially fatal Cushing’s and acromegaly, inflammation of the hands and feet that can lead to diabetes.

Cortendo, a Swedish-American biopharmaceutical company that has invested millions developing treatments for rare conditions such as Cushing’s syndrome(...)

Saverio Bellante told gardaí ‘I am guilty’ when charged with killing Tom O’Gorman at house in Castleknock

One of three siblings, Saverio Bellante was born on July 7th, 1979, in Palermo on the Italian island of Sicily. On Friday, Bellante was found not gui(...)

Israeli drugmaker Teva Pharmaceuticals has agreed to buy Allergan’s generic- drug business for about $40.5 billion.

Israeli drugmaker Teva Pharmaceuticals raised its full-year earnings forecast as it announced it agreed to buy Allergan’s generic-drug business. Teva(...)

Teva Pharmaceutical has built a 4.6 per cent share of Mylan over the past months. Photographer: Akos Stiller/Bloomberg

Teva Pharmaceutical, the Israeli drugmaker, is nearing a deal to acquire Allergan’s generics drug unit for between $40 billion and $45 billion, accord(...)

Minister for Enterprise Richard Bruton with American Chamber chief executive Mark Redmond and RIA executive director Laura Mahoney at the launch of the inaugural US-Ireland Research Innovation Awards

The inaugural US-Ireland Research Innovation Awards will be presented this Friday, May 15th, at the American Chamber of Commerce annual dinner in the (...)

Valeant Pharmaceuticals, the Canadian drugmaker known for its serial acquisitions, reported first-quarter profit that topped analysts’ estimates and r(...)

Some of the worst-performing funds in 2014 were ones managed by John Paulson, who rose to fame by making billions of dollars from a shrewd bet against the US housing market in the runup to the financial crisis.

If Steven A Cohen’s investment firm were operating as a hedge fund, it would have been one of the industry’s most profitable in 2014. Mr Cohen’s famil(...)

Botox is one of a number of pharmaceutical products made in Allergan’s Westport plant. Photograph: Shannon Stapleton/Files/Reuters

Allergan, the maker of Botox, has agreed to sell itself in a $66 billion (€53 billion) deal with fellow drugs group Actavis, with rival Valeant bowing(...)

Valeant had said it was willing to pay at least $200 a share and has the backing of Allergan’s largest shareholder -- activist investor Bill Ackman’s (pictured) Pershing Square Capital Management LP. ( Photograph: Scott Eells/Bloomberg)

Actavis has agreed to pay about $66 billion (€52.6bn) for Allergan, after the maker of Botox turned to the drugmaker to repel a hostile advance from V(...)